AzTrials
AzTrials

Mental Health ConditionsESPERNCT06805682

Prospective Cohort Study of Protected Children

An observational study of Mental Health Conditions and Physical Health Status, run by Assistance Publique - Hôpitaux de Paris at 7 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

A significant number of children are abused or neglected every year. This exposure is associated with short- and long-term consequences for their mental and somatic health. In France, 308,000 minors are benefiting from at least one child protective service or measure. Read more about this study

Who is it for?
Ages 0 to 42 months
How many people
220 participants
Where
7 sitesFrance
Study dates
18 Feb 2025to 17 Feb 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 0 to 42 months
  • All sexes
  • No healthy volunteers
  • Child

Study population: Children from the control cohort will be included in the participating services of 7 French departments (the territorial level responsible for CPS in France) not participating in the PEGASE program. The child protection measure can be exercised either in an institution, a foster family or an open environment service.

Who may be able to join

  • Child under the supervision of child protective services,
  • Arriving for the first time in a participating center,
  • Less than 42 months old (i.e. 3 and a half years),
  • Non-opposition of the holders of parental authority (in the event of impossibility to obtain the non-opposition of both holders of parental authority, the non-opposition of one of them will be obtained).

Who cannot join

  • Children whose child protection measure has not been confirmed by a judicial or administrative decision.

Trial locations and contacts

7 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Morgane MICHEL, MD contact

+33 1 57 27 89 68

morgane.michel@aphp.fr

7 sites in 1 country

France7 sites, 7 recruiting
  • Maternal and Child Protection - The Eure Department

    Évreux, France, 27000

    Doriane HASCOËT, MD, +33 2 32 31 31 65, doriane.hascoët@eure.fr

    Recruiting
  • Departmental institution to support - accompany - educate

    Lille, France, 59000

    Sophie HAMADACHE, MD, +33 3 27 41 89 02, hamadache.sophie@epdsae.fr

    Recruiting
  • Moselle Departmental Children's Centre

    Metz, France, 57050

    Fanny HUBER, MD, +33 3 87 34 64 00, F.Huber@cde-moselle.com

    Recruiting
  • Maternal and Child Protection

    Rouen, France, 76100

    Marianne LAINE, MD, + 33 2 35 03 55 55, marianne.laine@seinemaritime.fr

    Recruiting
  • Maternal and Child Protection

    Saint-Brieuc, France, 22000

    Françoise METAILLER-ARZEL, MD, +33 2 96 60 86 86, Francoise.METAILLERARZEL@cotesdarmor.fr

    Recruiting
  • Children and Family Home of the Loire

    Saint-Genest-Lerpt, France, 42530

    Anaïs MAILLIER, MD, +33 4 77 80 50 50, anais.maillier@fdef42.fr

    Recruiting
  • Departmental Observatory for Child Protection

    Toulon, France, 83000

    Kareen THIBAULT, MD, +33 4 83 95 00 00, kthibault@var.fr

    Recruiting

Other trials in France

About this study

Official title: PEGASE3, Experimental Program of a Standardized Health Protocol Applied to Children Who Benefited From a Child Protection Measure Before the Age of Five: Effectiveness and Efficiency

A significant number of children are abused or neglected every year. This exposure is associated with short- and long-term consequences for their mental and somatic health. In France, 308,000 minors are benefiting from at least one child protective service or measure. There are few data on the health status of this population, and how it is evolving. Against this backdrop, interventions are needed to address the many needs of these children early and comprehensively, both in the short and long term.

The PEGASE program, funded by the French government under Article 51, aims to ensure adequate medical follow-up - both somatic and psychiatric - for children taken into care by child protective services (CPS). An evaluation of the program's effectiveness and efficiency is needed to inform public decision-making on the appropriateness of extending it to all children under CPS's care. This requires the creation of a control cohort of children followed by CPS but not benefiting from the PEGASE program, the ESPER cohort (Prospective cohort study of protected children), which will enable us to carry out a comparative evaluation of the PEGASE program, as well as to provide information on the health of children followed by the CPS at the time of their placement and its evolution over time, data which are rare in France.

The main objective is to evaluate the effectiveness of the PEGASE program on the evolution of the mental health of children followed by the CPS after 2 years of follow-up.

Read the detailed description

A significant number of children are abused or neglected every year. This exposure is associated with short- and long-term consequences for their mental and somatic health, making child abuse a real challenge for society, both on an individual level, in terms of equal opportunities, and on a collective level, from a public health and economic point of view. In France, 308,000 minors benefit from at least one child protection service or measure. There are few data available on the health status of this population and its evolution over time, but they all point to the poor health status of children when first placed into care, with a particularly high prevalence of mental disorders, a low proportion of children benefiting from an initial health check-up, and poor quality of medical follow-up once in care.

In this context, interventions are needed to address early and comprehensively the many needs of children put into care, both in the short and long term. In particular, early detection and reduced delays in the initiation of appropriate medical care appear to have positive long-term effects, reducing medico-social needs. As such, the PEGASE program, which is funded by the French government under Article 51, was developed to ensure adequate medical follow-up - both somatic and psychiatric - for children taken into care by child protective services (CPS).

Children in the PEGASE program are monitored with regular, standardized check-ups, with an initial standardized check-up when the child enters the care facility followed by 20 regular assessments at fixed ages up to the age of 7. Most of these assessments are reinforced in PEGASE by the systematic use of standardized scales to identify potential disorders and developmental delays, so that the necessary care can be implemented at an early stage.

An evaluation of the program's effectiveness and efficiency is needed to inform public decision-making on the appropriateness of extending it to all children in care. As there is no control group in the PEGASE program, this requires the creation of a control cohort of children followed by CPS but not benefiting from the PEGASE program. This is the ESPER cohort (Prospective cohort study of protected children), which will enable us to carry out a comparative evaluation of the PEGASE program, as well as to provide information on the health of children taken into care by the CPS at the time of their placement, and on its evolution over time, data which are rare in France.

The primary objective is to evaluate the effectiveness of the PEGASE program on the evolution of the mental health of children followed by the CPS after 2 years of follow-up.

The secondary objectives are:

  • To evaluate the effectiveness of the PEGASE program on the evolution of children followed by the CPS after 1 and 2 years of follow-up, in terms of: mental health, physical health, development (communication, gross motor skills and fine motor skills), care pathway, and school integration,
  • To evaluate the cost-effectiveness of the PEGASE program after 2 years of follow-up, and its budgetary impact in the case of generalization,
  • To describe the health of children when they are put into care.

An ancillary study is also planned to compare the health of children followed by CPS to the health of children in the general population.

This is a comparative study with an external control group and propensity score matching, calculated from a multivariate logistic regression model that will include a priori: corrected age at inclusion, gender, gestational age, ASQ-SE and ASQ-3 scores at inclusion, reason for placement, current protective measure, and social situation of both parents.

The PEGASE program is already the subject of a separate protocol describing recruitment procedures and follow-up of children benefiting from the program.

The population included in the ESPER study are children taken into care by CPS in 7 volunteer departments not participating in the PEGASE program. They must be aged less than 42 months (i.e. 3 and a half years), arriving for the first time in a participating center, and the holders of parental authority must not object to participation in the study.

The children included the ESPER cohort will be followed as usual by the participating center during the two years of follow-up. Additional data collection by questionnaire will be added to the usual care at inclusion, and then at 1 and 2 years of follow-up either in person or by telephone by the study's local coordinators (if the child is no longer in the facility at the time of collection).

At the inclusion visit, parents or legal guardians will be informed of the study, and their non-opposition will be sought. All socio-demographic, health and school data will be collected by the local coordinators. The ASQ-SE and ASQ-3 questionnaires will be completed, as well as antenatal and pre-placement health data. The data will then be entered into the eCRF by the local coordinators.

At one year of follow-up, the local coordinators will collect health data (from the health records) and school data. If the child is no longer in the facility, data will be collected by telephone from the child's care takers, or from the parents (or holders of parental authority) if the child lives with them. The ASQ-SE and ASQ-3 questionnaires will be completed by the same person. The local coordinators will then enter the data into the tool. The 2-year follow-up visit will be identical to the 1-year visit.

It is planned to include 220 children in the ESPER cohort. The inclusion period is 24 months, and the duration of each child's participation in the study is 24 months.

Being tested
Usual Care
Keywords
Child Protective Services, Child Development, Mental health, Cohort study, Comparative study
Medical subject headings
Psychological Well-Being

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Usual CareOther

    Children will be followed using each CPS participating center's usual practices

Study groups in NCT06805682
Study groupRoleWhat they receive
ESPERChildren under the care of child protective services and followed using usual practices
Receives: Other: Usual Care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mental health

    The primary endpoint is the ASQ-SE questionnaire score after two years of follow-up, dichotomized into: 1/ Failure: the child is above the alert threshold defined for his/her age, indicating the need to initiate or maintain adapted care; 2/ Success: the child is below the age-defined alert threshold (i.e. "within the norm" for his or her age).

    The ASQ-SE assesses socio-emotional development, a reflection of mental health in young children. The higher the score, the more worrying the child's condition.

    As socio-emotional development evolves with age, nine questionnaires are available, depending on the child's age: 2, 6, 12, 18, 24, 30, 36, 48 and 60 months. The questionnaire is made up of around 36 items (the number of items varies according to the age of the child) and is associated with a score (the total score is a function of the number of items, and therefore differs according to age) and alert thresholds.

    Measured: two years of follow-up

Secondary outcomes (12)
  1. Mental health_ASQ-SE questionnaire

    • Standardized ASQ-SE score: in order to compensate for the variability of the total score scales according to age, the score obtained at the different ages will be standardized between 0 and 100
    • ASQ-SE questionnaire score dichotomized into success or failure

    Measured: 1 and 2 years of follow-up

  2. Body mass index

    Body mass index will be expressed in z-score, as a function of age and sex

    Measured: 1 and 2 years of follow-up

  3. Growth restriction

    Percentage of children whose height is below the fifth percentile for their age and sex on a standard growth curve

    Measured: 1 and 2 years of follow-up

  4. Communication skills

    Assessed with the ASQ-3 "Communication" subscale score. The ASQ-3 screens for developmental delays on five subscales. The lower the score, the more worrying the child's condition. Like the ASQ-SE, the ASQ-3 questions evolve with the child's age, with a maximum score that varies with age, and alert thresholds available for each questionnaire (at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 27, 30, 33, 36, 42, 48, 54 and 60 months).

    • The score will be dichotomized into failure (score below the alert threshold defined for their age for initiating or maintaining appropriate management) or success (score above the alert threshold), and standardized between 0 and 100 (similarly to the ASQ-SE)

    Measured: 1 and 2 years of follow-up

  5. Gross motor development

    • Assessed with the ASQ-3 "gross motor skills" subscale score.
    • The score will be both dichotomized as failure or success, and standardized between 0 and 100

    Measured: 1 and 2 years of follow-up

  6. Fine motor development

    • Assessed with the ASQ-3 "fine motor skills" subscale score.
    • The score will be dichotomized as failure or success, and standardized between 0 and 100

    Measured: 1 and 2 years of follow-up

  7. Care pathway

    Percentage of children with a complete vaccination protocol

    Measured: 1 and 2 years of follow-up

  8. School integration

    Number of days of schooling per week

    Measured: 1 and 2 years of follow-up

  9. Cost-effectiveness

    Incremental cost-effectiveness ratio in cost per child below the alert threshold for the ASQ-SE

    Measured: 2 years of follow-up

  10. Costs associated with the generalization of the program

    Direct costs associated with children's care and follow-up (healthcare consumption, cost of the PEGASE program…) will be calculated with and without the PEGASE program to assess the budgetary impact of its generalization

    Measured: extrapolation at 5 years after hypothetical generalization

  11. Developmental gains associated with the generalization of the program

    The number of children with normal development will be calculated with and without the PEGASE program to assess the health gains associated with its generalization

    Measured: extrapolation at 5 years after hypothetical generalization

  12. Children's health at admission

    Criteria 1 to 7

    Measured: measured at study inclusion

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Feb 2025
  2. Study start18 Feb 2025
  3. Primary completion17 Feb 2029 (estimated)
  4. Study completion17 Feb 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
220 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06805682
Sponsor's protocol ID
APHP230596
Other IDs
PREPS-22-0058, 2024-A00953-44
Acronym
ESPER
Status last verified
Apr 2026
First submitted
17 Jan 2025
Last updated
13 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Mental Health Conditions and Physical Health Status, run by Assistance Publique - Hôpitaux de Paris at 7 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Morgane MICHEL, MD (+33 1 57 27 89 68, morgane.michel@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mental health (time frame: two years of follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in